1. [18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
- Author
-
Cato C. Loeff, Willemijn van Gemert, Bastiaan M. Privé, Inge M. van Oort, Rick Hermsen, Diederik M. Somford, James Nagarajah, Linda Heijmen, and Marcel J. R. Janssen
- Subjects
PET/CT ,PSMA ,Fluciclovine ,Biochemical recurrence ,Prostate cancer (PCa) ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Aim The objective of this study was to compare the detection rates of [18F]PSMA-1007 and [18F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0.2–5.0 µg/L). Methods This was a prospective, single-center (Radboudumc; Nijmegen, The Netherlands), comparative phase II diagnostic imaging study (NCT04239742). The main inclusion criteria were histologically proven adenocarcinoma of the prostate, BCR after radical treatment with two consecutive (rising) PSA values (0.2–5.0 µg/L). Patients underwent both [18F]PSMA-1007 PET/CT and [18F]Fluciclovine PET/CT within two weeks. Both scans were blindly scored by three independent nuclear medicine physicians. Hereafter, a result per scan and region was generated by consensus. The primary outcome was to compare the detection rate on a patient and region level. Secondary objectives were to determine detection rate stratified for PSA value, inter-reader agreement, and SUV measurements. For lesion confirmation a composite reference score was established using follow-up data. Results Data of fifty patients were included, median age of 71 (IQR: 67–74) years and median PSA value of 0.38 (IQR: 0.30–1.55) µg/L. Detection rates were 68% (34/50) for [18F]PSMA-1007 and 42% (21/50) for [18F]Fluciclovine on a patient level (p
- Published
- 2024
- Full Text
- View/download PDF